Dec 26, 2013
Immune Pharmaceuticals: A Speculative Biotech Option For The Patient Investor
Nearly everyone, at some point in their lives, has an involuntary connection to an articulate, and well-crafted, turn-of-phrase.
Immune Pharmaceuticals Announces Focus on Capital Raising and Primary Listing in The United States
As a result of the merger, NASDAQ OMX Stockholm AB has advised, and the Company has agreed, to seek the transition of its Swedish listing to NASDAQ OMX First North Premier, which maintains access to Nordic country capital and liquidity for existing shareholders, while requiring less market specific regulation.